Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

26.70
+0.01030.04%
Post-market: 26.750.0511+0.19%16:10 EDT
Volume:202
Turnover:5K
Market Cap:5.34M
PE:- -
High:26.75
Open:26.75
Low:26.70
Close:26.69
52wk High:27.94
52wk Low:22.63
Shares:200.00K
Float Shares:200.00K
Volume Ratio:0.25
T/O Rate:0.10%
Dividend:0.41
Dividend Rate:1.55%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

ASX listed pharma boosted by weight loss drugs

Morning Star AU
·
Aug 31

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

India's GLP-1 Weight-Loss Drugs Stall at $14 Monthly Despite High Diabetes Rates

Deep News
·
Aug 29

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Simply Wall St.
·
Aug 29

Novo Nordisk A/S Series B Stock Rises Friday

Dow Jones
·
Aug 29

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

FDA Approves Lilly's Mounjaro to Cut Cardiovascular Event Risk in High-Risk Type 2 Diabetes Adults

Reuters
·
Aug 28

FDA Approves Lilly's Mounjaro (Tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes

THOMSON REUTERS
·
Aug 28

Novo Nordisk Share Price Already Reflects Plenty of Pessimism

Dow Jones
·
Aug 28